华昊中天医药-B(02563.HK) 发盈警,预计2024年度净亏损介乎1.46亿至1.51亿人民币,相较2023年度净亏损1.9亿人民币。亏损减少主要受惠于产品市场渗透提高导致销售收入增长、产品生产工艺优化所带来的销售成本降低以及严格控制销售开支带来的销售费用减少。(de/d)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.